OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Dahut on an NCI-Led Study Using MRI Screening to Detect Prostate Cancer

March 4th 2020

William L. Dahut, MD, senior investigator and section chief, Genitourinary Malignancies Branch, head, Prostate Cancer Clinical Research Section, clinical director and scientific director for clinical research, Center for Cancer Research, National Cancer Institute (NCI), discusses an NCI-led study that is using screening to detect prostate cancer.

Dr. Lopategui on the Implications of Genomic Sequencing in Lung Cancer

March 4th 2020

Jean Lopategui, MD, associate professor of pathology and director of Translational Genomics and of the Molecular Genetics Pathology Fellowship at Cedars-Sinai, discusses the implications of genomic sequencing in lung cancer.

Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian Cancer

March 4th 2020

Kathleen Moore, MD, director, Oklahoma TSET Phase I Clinical Trials Program, and associate professor, Section of Gynecologic Oncology, Jim and Christy Everest Endowed Chair in Cancer Research, director, Gynecologic Oncology Fellowship Program, associate director of Clinical Research, and medical director of the Clinical Trials Office, at Stephenson Cancer Center, discusses the role of mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Dr. Wright on Key Strategies in Using Radiation in Breast Cancer Treatment

March 3rd 2020

Jean Wright, MD, discusses key strategies in using radiation therapy to treat patients with breast cancer.

Dr. Chung on the Effect of Combo Therapies in Patients With Pancreatic Cancer

March 3rd 2020

Vincent Chung, MD, discusses the effect of gemcitabine, nab-paclitaxel (Abraxane), metformin, and dietary supplements on patients with pancreatic cancer.

Dr. Goodman on the Role of Transplant in T-Cell Lymphoma

March 3rd 2020

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the role of transplant in patients with T-cell lymphomas.

Dr. Branagan on Tandem Transplants in Multiple Myeloma

March 3rd 2020

Andrew Branagan, MD, discusses the research tandem transplants in patients with high-risk multiple myeloma.

Dr. Natale on the Utility of PD-L1 and TMB in Lung Cancer

March 3rd 2020

Ronald B. Natale, MD, medical director, Clinical Lung Cancer Program and assistant clinical professor of medicine, Cedars-Sinai, discusses the utility of PD-L1 expression and tumor mutational burden (TMB) in lung cancer.

Dr. Gerds on the State of Treatment in MPNs

March 3rd 2020

Aaron Gerds, MD, assistant professor of medicine in the Hematology and Medical Oncology Department at the Cleveland Clinic Taussig Cancer Institute, discusses the state of treatment in myeloproliferative neoplasms (MPNs).

Dr. Wang on the Safety Profile of KTE-X19 in MCL

March 3rd 2020

Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, according to results from the phase II ZUMA-2 trial.

Dr. Raphael on the Treatment Landscape of CLL

March 3rd 2020

Bruce G. Raphael, MD, discusses the treatment landscape of chronic lymphocytic leukemia.

Dr. Chern on Challenges Regarding Germline Testing in Ovarian Cancer

March 3rd 2020

Jeannie Chern, MD, discusses challenges with germline molecular testing for patients with ovarian cancer.

Dr. Raghav on Activating the RAS/RAF/MEK/ERK Pathway in CRC

March 3rd 2020

Kanwal Raghav, MBBS, MD, discusses the activation of the RAS/RAF/MET/ERK pathway in colorectal cancer.

Dr. Richardson on the FDA Approval of Isatuximab in Relapsed/Refractory Myeloma

March 3rd 2020

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the FDA approval of isatuximab-irfc (Sarclisa) for use in combination with pomalidomide (Pomalyst) and dexamethasone in relapsed/refractory multiple myeloma.

Dr. Hellmann on Benefit of PARP Inhibitors in Patients With Ovarian Cancer

March 3rd 2020

Mira C. Hellmann, MD, discusses the benefit of PARP inhibitors in patients with ovarian cancer.

Dr. Figlin on Novel Combinations in Kidney Cancer Treatment

March 2nd 2020

Robert A. Figlin, MD, discusses novel combinations in the treatment of patients with kidney cancer.

Experts Share Common Misconceptions in Their Fields

February 29th 2020

OncLive interviewed experts at the State of the Science Summits™ in February 2020 on common misconceptions in their respective fields.

Dr. Ramchandran on Considerations for Palliative Care in Thoracic Cancers

February 29th 2020

Kavitha Ramchandran, MD, discusses considerations as patients with thoracic malignancies enter palliative care.

Dr. Khaled on Recognition and Treatment of TA-TMA

February 29th 2020

Samer K. Khaled, MD, discusses current recognition and treatment strategies for transplant-associated thrombotic microangiopathy.

Dr. Piotrowska on Eligibility Criteria for Osimertinib in Lung Cancer Treatment

February 29th 2020

Zofia Piotrowska, MD, MHS, discusses the patient populations eligible to receive osimertinib as treatment for lung cancer.